December 2019

The Column Group Raises a $725 Million Fourth Fund

The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, the firm will continue to execute on the strategy it has deployed since inception – assembling a focused

The Column Group Raises a $725 Million Fourth Fund Read More »

Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE

The Column Group Raises a $725 Million Fourth Fund

RAPT Therapeutics Report Third Quarter 2019 Financial Results and Recent Highlights

Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

RAPT Therapeutics Appoints Rodney Young As Chief Financial Officer